PineBridge Investments L.P. boosted its position in shares of Cantel Medical Corp. (NYSE:CMN) by 3.8% during the second quarter, Holdings Channel reports. The fund owned 4,548 shares of the company’s stock after buying an additional 165 shares during the period. PineBridge Investments L.P.’s holdings in Cantel Medical Corp. were worth $312,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quadrature Capital Ltd bought a new stake in Cantel Medical Corp. during the first quarter worth $232,000. UBS Group AG increased its stake in Cantel Medical Corp. by 2.6% in the first quarter. UBS Group AG now owns 52,630 shares of the company’s stock worth $3,756,000 after buying an additional 1,348 shares during the last quarter. State Street Corp increased its stake in Cantel Medical Corp. by 1.4% in the first quarter. State Street Corp now owns 698,437 shares of the company’s stock worth $49,838,000 after buying an additional 9,417 shares during the last quarter. Cypress Wealth Advisors LLC bought a new stake in Cantel Medical Corp. during the first quarter worth $210,000. Finally, Zebra Capital Management LLC increased its stake in Cantel Medical Corp. by 20.2% in the first quarter. Zebra Capital Management LLC now owns 13,431 shares of the company’s stock worth $958,000 after buying an additional 2,254 shares during the last quarter. Institutional investors own 81.61% of the company’s stock.

Shares of Cantel Medical Corp. (NYSE:CMN) opened at 79.52 on Thursday. The firm has a market capitalization of $3.29 billion, a P/E ratio of 58.17 and a beta of 1.66. Cantel Medical Corp. has a 12-month low of $49.12 and a 12-month high of $81.33. The company has a 50-day moving average price of $74.28 and a 200-day moving average price of $70.18.

A number of research firms recently weighed in on CMN. Needham & Company LLC began coverage on Cantel Medical Corp. in a report on Wednesday, August 24th. They issued a “hold” rating for the company. Benchmark Co. began coverage on Cantel Medical Corp. in a report on Monday, August 29th. They issued a “buy” rating and a $83.00 price objective for the company.

About Cantel Medical Corp.

Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

5 Day Chart for NYSE:CMN

Want to see what other hedge funds are holding CMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMN).

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.